secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-09-28T12:01:07+00:00
Accession:  0001664710-26-000056
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Keros doses first patient in Phase 2 rinvatercept trial in DMD; initial data expected in H1 2027
--------------------------------------------------------------------------------

- First patient dosed in open-label, multi-cohort Phase 2 basket trial (NCT07704099) of rinvatercept in late-ambulatory and early non-ambulatory Duchenne muscular dystrophy patients.
- Primary objective is safety and tolerability; key secondary objectives include pharmacokinetics, anti-drug antibodies, body composition and skeletal muscle, motor, cardiac and pulmonary function.
- Company expects initial data from the trial in the first half of 2027.
- CEO Jasbir Seehra said rinvatercept is designed to modulate key regulators of muscle and bone biology, advancing Keros' neuromuscular strategy.
- Gina O'Grady of Starship Children's Hospital said DMD still places a significant burden on patients and the need for additional options remains high.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/0001664710-26-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/kros-20260928.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer